Lumateperone Approved for Major Depression Conexiant
US FDA expands use of J&J’s Caplyta as add-on depression drug PharmaLive
J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder Fierce Pharma
FDA approval of CAPLYTA® has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder Investing News Network
Depressive Disorders Market to Reach USD 27.3 Billion by 2034 openPR.com
"I thought I nearly died": Everything Roman Kemp has said about his severe battle with anxiety Cosmopolitan
Chinese Scientists Discover Key Antidepressant Treatment Mechanism Yicai Global
PANDA Revisited: Sertraline’s Early Benefit Missed Medscape
Chinese scientists uncover key mechanism behind rapid antidepressant therapies; article published in Nature journal Global Times
New Ketamine Derivatives Target Adenosine Signaling to Enhance Antidepressant Effects geneonline.com
